Receipt: https://pmc.ncbi.nlm.nih.gov/articles/PMC6751327/ Read: 2026-11-12, curl with browser user agent, HTML converted to text, HTTP 200 Note: Eleven men, 6 hour IV NAD+ infusion; no adverse events reported. (Text converted from HTML; the superscript plus in NAD+ is joined to the word.) --- Abstract Accumulating evidence suggests that active maintenance of optimal levels of the essential pyridine nucleotide, nicotinamide adenine dinucleotide (NAD+) is beneficial in conditions of either increased NAD+ turnover or inadequate synthesis, including Alzheimer’s disease and other neurodegenerative disorders and the aging process. While studies have documented the efficacy of some NAD+ precursors such as nicotinamide riboside (NR) in raising plasma NAD+, no data are currently available on the fate of directly infused NAD+ in a human cohort. This study, therefore, documented changes in plasma and urine levels of NAD+ and its metabolites during and after a 6 h 3 μmol/min NAD+ intravenous (IV) infusion. Surprisingly, no change in plasma (NAD+) or metabolites [nicotinamide, methylnicotinamide, adenosine phosphoribose ribose (ADPR) and nicotinamide mononucleotide (NMN)] were observed until after 2 h. Increased urinary excretion of methylnicotinamide and NAD+ were detected at 6 h, however, no significant rise in urinary nicotinamide was observed. This study revealed for the first time that: (i) at an infusion rate of 3 μmol/min NAD+ is rapidly and completely removed from the plasma for at least the first 2 h; (ii) the profile of metabolites is consistent with NAD+ glycohydrolase and NAD+ pyrophosphatase activity; and (iii) urinary excretion products arising from an NAD+ infusion include NAD+ itself and methyl nicotinamide (meNAM) but not NAM. Keywords: NAD+, nicotinamide (NAM), ADP ribose, methyl nicotinamide, nicotinamide mononucleotide Introduction The parent pyridine nucleotide, nicotinamide adenine dinucleotide (NAD+) is present in all cells of the body and is essential for cell viability and function. As a cofactor responsible for electron transport into the respiratory chain, NAD+ and its redox couple NADH are central to energy (ATP) production in the mitochondria via oxidative phosphorylation. The phosphorylated metabolite of NAD+, NADP+ with its redox couple NADPH also provides the reducing power to drive a number of anabolic reactions, including cholesterol and nucleic acid synthesis, elongation of fatty acids and regeneration of glutathione (GSH), one of the body’s main antioxidants. Overall this family of pyridine nucleotides, [NAD(P)(H)], contributes to the redox exchange of over 400 enzyme reactions. Importantly, when acting as a redox couple NAD+ is not consumed. However, NAD+ also serves as a substrate for a number of other important metabolic processes and is therefore consumed as a consequence of their chemical reactions, potentially depleting the tissue of NAD+. Included in this number are reactions driven by the poly adenosine phosphoribose-ribose (ADPR) family of enzymes (PARP 1–17) controlling DNA repair and nuclear stability, epigenetic control enzymes (Sirt1–7), intercellular immune communication (CD38/CD157) and neuronal regeneration (SARM1; Essuman et al., 2017 ). The potential exists therefore for the disruption of cellular metabolism at multiple levels in conditions where NAD+ consumption by these enzymes exceeds NAD+ supply or synthesis. The clinical importance of maintaining cellular NAD+ levels was established early in the last century with the finding that pellagra, a disease characterized by diarrhea, dermatitis, dementia and death, could be cured with foods containing the NAD+ precursor niacin (also known as vitamin B 3 ; Goldberger, 1914 ). Although pellagra is rare in developed countries, cellular conc [...] east the first 2 h; (ii) the profile of metabolites is consistent with NAD+ glycohydrolase and NAD+ pyrophosphatase activity; and (iii) urinary excretion products arising from an NAD+ infusion include NAD+ itself and methyl nicotinamide (meNAM) but not NAM. Keywords: NAD+, nicotinamide (NAM), ADP ribose, methyl nicotinamide, nicotinamide mononucleotide Introduction The parent pyridine nucleotide, nicotinamide adenine dinucleotide (NAD+) is present in all cells of the body and is essential for cell viability and function. As a cofactor responsible for electron transport into the respiratory chain, NAD+ and its redox couple NADH are central to energy (ATP) production in the mitochondria via oxidative phosphorylation. The phosphorylated metabolite of NAD+, NADP+ with its redox couple NADPH also provides the reducing power to drive a number of anabolic reactions, including cholesterol and nucleic acid synthesis, elongation of fatty acids and regeneration of glutathione (GSH), one of the body’s main antioxidants. O [...] [...] + itself and methyl nicotinamide (meNAM) but not NAM. Keywords: NAD+, nicotinamide (NAM), ADP ribose, methyl nicotinamide, nicotinamide mononucleotide Introduction The parent pyridine nucleotide, nicotinamide adenine dinucleotide (NAD+) is present in all cells of the body and is essential for cell viability and function. As a cofactor responsible for electron transport into the respiratory chain, NAD+ and its redox couple NADH are central to energy (ATP) production in the mitochondria via oxidative phosphorylation. The phosphorylated metabolite of NAD+, NADP+ with its redox couple NADPH also provides the reducing power to drive a number of anabolic reactions, including cholesterol and nucleic acid synthesis, elongation of fatty acids and regeneration of glutathione (GSH), one of the body’s main antioxidants. Overall this family of pyridine nucleotides, [NAD(P)(H)], contributes to the redox exchange of over 400 enzyme reactions. Importantly, when acting as a redox couple NAD+ [...] [...] process. While studies have documented the efficacy of some NAD+ precursors such as nicotinamide riboside (NR) in raising plasma NAD+, no data are currently available on the fate of directly infused NAD+ in a human cohort. This study, therefore, documented changes in plasma and urine levels of NAD+ and its metabolites during and after a 6 h 3 μmol/min NAD+ intravenous (IV) infusion. Surprisingly, no change in plasma (NAD+) or metabolites [nicotinamide, methylnicotinamide, adenosine phosphoribose ribose (ADPR) and nicotinamide mononucleotide (NMN)] were observed until after 2 h. Increased urinary excretion of methylnicotinamide and NAD+ were detected at 6 h, however, no significant rise in urinary nicotinamide was observed. This study revealed for the first time that: (i) at an infusion rate of 3 μmol/min NAD+ is rapidly and completely removed from the plasma for at least the first 2 h; (ii) the profile of metabolites is consistent with NAD+ glycohydrolase and NAD+ pyrophosphatase activity; and (iii) urinary excretion products arising from an NAD+ infusion include NAD [...] [...] oshino et al., 2011 , 2018 ; Mills et al., 2016 ; Airhart et al., 2017 ), the metabolic fate and pharmacokinetic properties of IV NAD+ administration are yet to be reported in humans. This study, therefore, presents for the first time the changes in concentrations of NAD+ and its metabolites during an IV infusion of NAD+ in a cohort of healthy male participants. Materials and Methods Participants Eleven (Test n = 8, Control n = 3) male participants aged 30–55 years were recruited via advertisements on radio, TV and social media outlets. All participants had a BMI less than 30 kg/m 2 (Test average BMI = 27.5 ± 2.5 kg/m 2 ; Control average BMI = 24.6 ± 6.5 kg/m 2 ), were not diabetic, smoked less than 1 cigarette and consumed less than 2 standard alcoholic drinks per day. Individuals taking lipid lowering or anti-inflammatory drugs, who had a history of liver or renal failure or recently experienced a microbial infection, trauma or any other significant or [...] [...] f optimal levels of the essential pyridine nucleotide, nicotinamide adenine dinucleotide (NAD+) is beneficial in conditions of either increased NAD+ turnover or inadequate synthesis, including Alzheimer’s disease and other neurodegenerative disorders and the aging process. While studies have documented the efficacy of some NAD+ precursors such as nicotinamide riboside (NR) in raising plasma NAD+, no data are currently available on the fate of directly infused NAD+ in a human cohort. This study, therefore, documented changes in plasma and urine levels of NAD+ and its metabolites during and after a 6 h 3 μmol/min NAD+ intravenous (IV) infusion. Surprisingly, no change in plasma (NAD+) or metabolites [nicotinamide, methylnicotinamide, adenosine phosphoribose ribose (ADPR) and nicotinamide mononucleotide (NMN)] were observed until after 2 h. Increased urinary excretion of methylnicotinamide and NAD+ were detected at 6 h, however, no significant rise in urinary nicotinamide wa [...] [...] ncouraged to drink water to remain normally hydrated. No other beverage types were permitted. To ensure adequate energy intake was maintained for participants during the 6 h infusion the IV solution also contained 0.1% dextrose, providing approximately 2,000 calories over the 6 h infusion period. Infusion Protocol Participants were randomized to either the Test ( n = 8) or Control ( n = 3) group. Participants in the Test group were intravenously administered 750 mg NAD+ in normal saline (Archway Apothecary, Covington, LA, USA) over a 6 h period (infusion rate = ~2 mg/min ≡ 3 μmoles/min). This dosage of NAD+ was derived empirically and reflects a common dosing regimen in clinics (e.g., Springfield Wellness Clinic, Springfield, LA, USA) which regularly provide IV NAD+ infusions in clinical practice. Participants in the Control group were intravenously administered normal saline over a 6 h period. Clinical administration and supervision of the IV infusions and sample collection were carried out at the Springfield Wellness Center, Springf [...] [...] tistically significant when p < 0.05. Ethics This study was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. Ethical approval was obtained from the William Carey University Institutional Review Board, Hattiesburg, MS (Protocol #2017-12). Informed consent was obtained from all participants. Results Safety No adverse events were observed during the 6 h infusion with either placebo (saline) or test (NAD+) cohorts. A significant decrease in activity (1.3, 57, 3.6 units/L) for the liver function enzymes GGT, LD and AST, respectively was observed at 8 h after initiation of the NAD+ infusion ( Table 1 ). No significant change in activity for any liver function marker was apparent at 8 h in the placebo (saline) treated samples, however low sample number may reduce discrimination sensitivity. A significant increase of 2.75 μmoles/L in plasma bilirubin was also observed. However, none of the changes were consid [...]